> These agents together were tested in orthotopic mouse models of PDAC, where tumour cells are implanted in a location that closely resembles their natural environment in the pancreas.

Ugh, of course: "in mice"!

> The combination therapy also led to significant regression in genetically engineered mouse tumours and in human cancer tissues grown in lab mice, known as patient-derived tumour xenografts (PDX).

OK, maybe "in human tissue grown in mice" isn't so bad.

Fingers crossed. Pancreatic cancer is terrible.